Piper Jaffray Upgrades Amneal Pharmaceuticals (AMRX) to Overweight
Tweet Send to a Friend
Piper Jaffray analyst David Amsellem upgraded Amneal Pharmaceuticals (NYSE: AMRX) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
